Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
40
NLSP Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-24.38%
Day range:
$1.53 - $1.60
52-week range:
$1.47 - $18.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
15.2K
Avg. volume:
3.9M
1-year change:
-88.21%
Market cap:
$6M
Revenue:
--
EPS (TTM):
-$6.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$820.9K | -$0.21 | -95.08% | -273.39% | $10.07 |
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$7.3M | -$1.19 | -96.36% | -11.56% | $83.60 |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$0.59 | -- | -247.27% | $78.67 |
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -8.38% | $10.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NLSP
NLS Pharmaceutics
|
$1.58 | -- | $6M | -- | $0.00 | 0% | -- |
|
ACIU
AC Immune SA
|
$2.29 | $10.07 | $226.6M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.54 | $30.00 | $8.1M | -- | $0.00 | 0% | 13.93x |
|
CRSP
CRISPR Therapeutics AG
|
$42.12 | $83.60 | $3.6B | -- | $0.00 | 0% | -- |
|
MLTX
MoonLake Immunotherapeutics
|
$38.67 | $78.67 | $2.4B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$4.33 | $10.78 | $159.7M | -- | $0.00 | 0% | 21.67x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NLSP
NLS Pharmaceutics
|
-- | 3.791 | -- | -- |
|
ACIU
AC Immune SA
|
-- | 5.657 | -- | 1.66x |
|
ADXN
Addex Therapeutics
|
-- | 3.522 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 2.038 | -- | 21.97x |
|
MLTX
MoonLake Immunotherapeutics
|
-- | 2.430 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 3.153 | -- | 14.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$21.2M | -37.26% | -37.26% | -1386.46% | $5.4M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
$35M | -$64.6M | -18.65% | -18.65% | -184.54% | -$50.3M |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$49.6M | -- | -- | -- | -$48.6M |
|
MOLN
Molecular Partners AG
|
-- | -$16.8M | -37.36% | -37.36% | -2407.93% | -$14.2M |
NLS Pharmaceutics vs. Competitors
-
Which has Higher Returns NLSP or ACIU?
AC Immune SA has a net margin of -- compared to NLS Pharmaceutics's net margin of -1389.36%. NLS Pharmaceutics's return on equity of -- beat AC Immune SA's return on equity of -37.26%.
Company Gross Margin Earnings Per Share Invested Capital NLSPNLS Pharmaceutics-- -- -- ACIUAC Immune SA-- -$0.18 $124.3M -
What do Analysts Say About NLSP or ACIU?
NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 15089.87%. On the other hand AC Immune SA has an analysts' consensus of $10.07 which suggests that it could grow by 339.68%. Given that NLS Pharmaceutics has higher upside potential than AC Immune SA, analysts believe NLS Pharmaceutics is more attractive than AC Immune SA.
Company Buy Ratings Hold Ratings Sell Ratings NLSPNLS Pharmaceutics0 0 0 ACIUAC Immune SA3 0 0 -
Is NLSP or ACIU More Risky?
NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.632%.
-
Which is a Better Dividend Stock NLSP or ACIU?
NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLSP or ACIU?
NLS Pharmaceutics quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.3M. NLS Pharmaceutics's net income of -- is lower than AC Immune SA's net income of -$18M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLSPNLS Pharmaceutics-- -- -- -- ACIUAC Immune SA-- -- $1.3M -$18M
-
Which has Higher Returns NLSP or ADXN?
Addex Therapeutics has a net margin of -- compared to NLS Pharmaceutics's net margin of -2841.85%. NLS Pharmaceutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital NLSPNLS Pharmaceutics-- -- -- ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About NLSP or ADXN?
NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 15089.87%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that NLS Pharmaceutics has higher upside potential than Addex Therapeutics, analysts believe NLS Pharmaceutics is more attractive than Addex Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings NLSPNLS Pharmaceutics0 0 0 ADXNAddex Therapeutics0 0 0 -
Is NLSP or ADXN More Risky?
NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.
-
Which is a Better Dividend Stock NLSP or ADXN?
NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLSP or ADXN?
NLS Pharmaceutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. NLS Pharmaceutics's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLSPNLS Pharmaceutics-- -- -- -- ADXNAddex Therapeutics13.93x -- $62.3K -$1.8M
-
Which has Higher Returns NLSP or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to NLS Pharmaceutics's net margin of -106.6%. NLS Pharmaceutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.
Company Gross Margin Earnings Per Share Invested Capital NLSPNLS Pharmaceutics-- -- -- CRSPCRISPR Therapeutics AG-- -$0.44 $1.9B -
What do Analysts Say About NLSP or CRSP?
NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 15089.87%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 98.48%. Given that NLS Pharmaceutics has higher upside potential than CRISPR Therapeutics AG, analysts believe NLS Pharmaceutics is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings NLSPNLS Pharmaceutics0 0 0 CRSPCRISPR Therapeutics AG12 11 1 -
Is NLSP or CRSP More Risky?
NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.
-
Which is a Better Dividend Stock NLSP or CRSP?
NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLSP or CRSP?
NLS Pharmaceutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. NLS Pharmaceutics's net income of -- is lower than CRISPR Therapeutics AG's net income of -$37.3M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLSPNLS Pharmaceutics-- -- -- -- CRSPCRISPR Therapeutics AG-- -- $35M -$37.3M
-
Which has Higher Returns NLSP or MLTX?
MoonLake Immunotherapeutics has a net margin of -- compared to NLS Pharmaceutics's net margin of --. NLS Pharmaceutics's return on equity of -- beat MoonLake Immunotherapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLSPNLS Pharmaceutics-- -- -- MLTXMoonLake Immunotherapeutics-- -$0.72 -- -
What do Analysts Say About NLSP or MLTX?
NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 15089.87%. On the other hand MoonLake Immunotherapeutics has an analysts' consensus of $78.67 which suggests that it could grow by 103.43%. Given that NLS Pharmaceutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe NLS Pharmaceutics is more attractive than MoonLake Immunotherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings NLSPNLS Pharmaceutics0 0 0 MLTXMoonLake Immunotherapeutics11 1 0 -
Is NLSP or MLTX More Risky?
NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MoonLake Immunotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NLSP or MLTX?
NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MoonLake Immunotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. MoonLake Immunotherapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLSP or MLTX?
NLS Pharmaceutics quarterly revenues are --, which are smaller than MoonLake Immunotherapeutics quarterly revenues of --. NLS Pharmaceutics's net income of -- is lower than MoonLake Immunotherapeutics's net income of -$45.6M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while MoonLake Immunotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus -- for MoonLake Immunotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLSPNLS Pharmaceutics-- -- -- -- MLTXMoonLake Immunotherapeutics-- -- -- -$45.6M
-
Which has Higher Returns NLSP or MOLN?
Molecular Partners AG has a net margin of -- compared to NLS Pharmaceutics's net margin of -2408.81%. NLS Pharmaceutics's return on equity of -- beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital NLSPNLS Pharmaceutics-- -- -- MOLNMolecular Partners AG-- -$0.34 $165M -
What do Analysts Say About NLSP or MOLN?
NLS Pharmaceutics has a consensus price target of --, signalling upside risk potential of 15089.87%. On the other hand Molecular Partners AG has an analysts' consensus of $10.78 which suggests that it could grow by 148.97%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings NLSPNLS Pharmaceutics0 0 0 MOLNMolecular Partners AG3 1 0 -
Is NLSP or MOLN More Risky?
NLS Pharmaceutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NLSP or MOLN?
NLS Pharmaceutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NLS Pharmaceutics pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLSP or MOLN?
NLS Pharmaceutics quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. NLS Pharmaceutics's net income of -- is lower than Molecular Partners AG's net income of -$12.8M. Notably, NLS Pharmaceutics's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NLS Pharmaceutics is -- versus 21.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLSPNLS Pharmaceutics-- -- -- -- MOLNMolecular Partners AG21.67x -- $787.5K -$12.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
